Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired ...

Rhythm Pharmaceuticals (RYTM) added ~8% in the premarket on Friday after the U.S. Food and Drug Administration (FDA) approved a label expansion for its lead asset, setmelanotide, to allow its use in ...

Find latest healthcare news from every corner of the globe at Reuters.com, your online source for breaking international news ...

Rhythm Pharmaceuticals (NASDAQ:RYTM) announced that the U.S. Food and Drug Administration has approved IMCIVREE ...

The U.S. Food and Drug Administration (FDA) on Thursday approved an expanded indication for Rhythm Pharmaceuticals Inc.’s RYTM Imcivree (setmelanotide) to treat acquired hypothalamic obesity (HO). The ...

Alfasigma’s buzzer-beater bet on GSK’s rare liver disease prospect has paid off. | Lynavoy is now the first FDA-approved product that can treat cholestatic pruritus in patients with primary biliary ...

The U.S. Food and Drug Administration expanded the use of Rhythm Pharmaceuticals’  therapy for a rare form of obesity ​caused ...

Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery and development, ...

Parents should check their medicine cabinets immediately after nearly 90,000 bottles of children’s ibuprofen were recalled.

Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...

Chugai Pharmaceutical Co. fell 7.3%, the largest intraday decline since August 2025, after the company said it had ended the ...

ICH stability chambers with continuous monitoring for long-term, intermediate, and accelerated studies supporting FDA ...